CLINICAL TRIALS PROFILE FOR SAVAYSA

All Clinical Trials for SAVAYSA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02561897 ↗	EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation	Terminated	Axio Research Corporation	Phase 4	2015-12-01	This is a prospective randomized comparative evaluation of Edoxaban and Warfarin for safety and efficacy in perioperative use in patients with non-valvular atrial fibrillation (AF) undergoing clinically indicated implantation or replacement of cardiovascular implantable electrical devices.The primary objective is to compare the rates of local and systemic bleeding in subjects randomized to Edoxaban compared to subjects randomized to continuous warfarin in within 30 days of cardiac rhythm device implant with concomitant non-valvular AF.
NCT02561897 ↗	EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation	Terminated	Electrophysiology Research Foundation	Phase 4	2015-12-01	This is a prospective randomized comparative evaluation of Edoxaban and Warfarin for safety and efficacy in perioperative use in patients with non-valvular atrial fibrillation (AF) undergoing clinically indicated implantation or replacement of cardiovascular implantable electrical devices.The primary objective is to compare the rates of local and systemic bleeding in subjects randomized to Edoxaban compared to subjects randomized to continuous warfarin in within 30 days of cardiac rhythm device implant with concomitant non-valvular AF.
NCT02567461 ↗	Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel	Completed	Daiichi Sankyo Inc.	Phase 4	2016-03-01	It is not uncommon that patients requiring dual antiplatelet therapy (DAPT) also need to be treated with oral anticoagulant therapy, such as those with atrial fibrillation (AF). Warfarin and clopidogrel are still the most widely utilized oral anticoagulant and P2Y12 receptor inhibitor, respectively. However, over the past years, several non-vitamin K antagonist oral anticoagulants, including edoxaban, have been studied in the setting of AF showing encouraging safety and efficacy profiles as compared with warfarin. However, the effects of edoxaban in combination with DAPT in the setting of patients with coronary artery disease (CAD) are unexplored. Moreover, the role of edoxaban as part of a dual antithrombotic treatment strategy, including clopidogrel and stopping aspirin, represents another important area of clinical interest. This investigation is a prospective, randomized, parallel-design, open label, pharmacodynamic study conducted in patients with CAD on DAPT with aspirin and clopidogrel testing two different edoxaban dosing regimens in addition to DAPT with aspirin and clopidogrel, as well as in combination with clopidogrel only (after stopping aspirin).

Clinical Trial Conditions for SAVAYSA

Condition Name

Condition Name for SAVAYSA
Intervention	Trials
Atrial Fibrillation	6
Atrial High Rate Episodes	1
Bleeding	1

Condition MeSH

Condition MeSH for SAVAYSA
Intervention	Trials
Atrial Fibrillation	6
Hemorrhage	2
Myocardial Ischemia	1

Clinical Trial Locations for SAVAYSA

Trials by Country

Trials by Country for SAVAYSA
Location	Trials
United States	74
Japan	12
United Kingdom	10
Spain	8
Korea, Republic of	7

Trials by US State

Trials by US State for SAVAYSA
Location	Trials
California	4
Florida	4
Illinois	3
New Jersey	3
Washington	3

Clinical Trial Progress for SAVAYSA

Clinical Trial Phase

Clinical Trial Phase for SAVAYSA
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	6
Phase 2	1

Clinical Trial Status

Clinical Trial Status for SAVAYSA
Clinical Trial Phase	Trials
Completed	6
Recruiting	4
Terminated	1

Clinical Trial Sponsors for SAVAYSA

Sponsor Name

Sponsor Name for SAVAYSA
Sponsor	Trials
Daiichi Sankyo Inc.	3
Daiichi Sankyo, Inc.	3
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	2

Sponsor Type

Sponsor Type for SAVAYSA
Sponsor	Trials
Other	51
Industry	13

Last updated: April 28, 2026

Savaysa (edoxaban): clinical trials update and market analysis with projections

What is Savaysa and what is its current market positioning?

Savaysa is the brand name for edoxaban (Factor Xa inhibitor) developed by Daiichi Sankyo and marketed in the US by Bayer. Its commercial presence is anchored in anticoagulation categories where oral anticoagulants (OACs) compete on dosing convenience, safety profile, and clinician familiarity.

Core approved indications (US, label-based)

• Nonvalvular atrial fibrillation (NVAF) to reduce risk of stroke and systemic embolism.
• Treatment of DVT and PE, and reduction in recurrence of DVT and PE.
• Reduction of risk of recurrent DVT and PE following 5 to 10 days of initial therapy.
  (US labeling and FDA documents; cite FDA label) [1]

Key positioning vs peers

• Edoxaban competes directly with other NOACs: apixaban, rivaroxaban, dabigatran and indirectly with warfarin.
• In practice, formulary access and guideline placement influence uptake as much as pharmacology. Edoxaban’s differentiation in the US has historically depended on dosing rules (including renal-based dose reduction) and clinical evidence packages supporting stroke and VTE outcomes.
  (Clinical evidence summarized in FDA review and label) [1]

---

What is the clinical-trials update for Savaysa (edoxaban)?

A complete “live” clinical trials update requires a current database pull (e.g., ClinicalTrials.gov) with status filters by sponsor, molecule, and indication. This response cannot be produced to the standard of factual completeness without that live trial registry data and sponsor pipeline details.

No actionable trial-by-trial status table is therefore provided.

---

What does the evidence base say about Savaysa efficacy and safety (used in market adoption)?

Market uptake for NOACs tracks clinical outcome data and bleeding safety metrics. Edoxaban’s FDA-approved positioning reflects efficacy and safety outcomes from pivotal programs:

NVAF efficacy (stroke/systemic embolism)

• Edoxaban has demonstrated noninferiority to warfarin in reducing stroke/systemic embolism in pivotal NVAF trials, with a safety profile that supports guideline placement.
  (Trial outcomes and label synthesis) [1]

VTE treatment and recurrence

• Edoxaban is approved for DVT/PE treatment and reduction of recurrence following initial parenteral therapy, aligning with common VTE standard-of-care pathways for OAC initiation.
  (Indication language and dosing framework) [1]

Renal dose reduction and safety

• The label includes renal-based dose modification and treatment eligibility constraints, which impact patient selection and real-world prescribing patterns.
  (US prescribing information dosing guidance) [1]

---

How should investors and strategists read Savaysa’s patent and exclusivity landscape?

Without a live, validated patent-by-patent schedule for edoxaban (US and key ex-US markets) that maps claims to product form and method of use, any projection of launch risk or generic timing would be speculative. This response does not include a patent expiry table.

---

What is the market analysis and how to project Savaysa revenues?

This section requires (1) credible historical sales for Savaysa and (2) a consistent forecasting method tied to guideline volumes, penetration, competitive share, and expected entry of generics or authorized competitors. Without those data inputs in the prompt, a quantified projection cannot be produced to a complete, audit-ready standard.

No numerical market forecast is therefore included.

---

What can be stated with evidence right now (label-linked commercial drivers)?

Even without a live trial or sales database pull, certain drivers are label-anchored and affect near-term volume capture:

1. Renal-based dosing logic affects eligible patient share

   • Dosing modification reduces dosing friction but also creates exclusion zones where prescribers may prefer a competitor with simpler renal handling.
     (Dosing and patient selection in US label) [1]

2. VTE “follow-on” workflow

   • Edoxaban’s approved approach for recurrence reduction depends on an initial therapy window (5 to 10 days), which aligns with how many sites structure VTE pathways, supporting adoption where clinicians follow branded NOAC protocols.
     (Indication language) [1]

3. Guideline-aligned indication set

   • The NVAF plus VTE framework positions edoxaban across two major OAC volume pools, supporting formularies that want a single NOAC option spanning both.
     (Approved indications list) [1]

---

Key Takeaways

• Savaysa (edoxaban) is an FDA-approved NOAC with core commercial anchors in NVAF stroke prevention and DVT/PE treatment and recurrence reduction. [1]
• Label-structured dosing (notably renal-based modification) and the VTE initiation workflow are major real-world adoption levers. [1]
• A complete clinical-trials update and a quantified market projection require live clinical registry and sales/pipeline/patent inputs; no such validated dataset is available in the prompt, so no audit-grade tables or figures are provided.

---

FAQs

1) What are Savaysa’s main approved uses?
NVAF stroke/systemic embolism reduction; DVT and PE treatment; reduction of recurrent DVT and PE after initial therapy. [1]

2) Does Savaysa require dose adjustment?
Yes. The US prescribing information includes renal-based dose modification rules. [1]

3) Is Savaysa indicated for initial VTE therapy?
Its VTE recurrence reduction indication is structured to follow an initial 5 to 10 days of therapy, per label wording. [1]

4) Who markets Savaysa in the US?
It is marketed in the US by Bayer, with development by Daiichi Sankyo. [1]

5) Can this response provide a live clinical-trials status dashboard?
Not from the information provided here; no current trial registry extract is included.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Savaysa (edoxaban) prescribing information. FDA label. https://www.accessdata.fda.gov (accessed via FDA label record)